Cargando…

Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer

Biomarkers of response are needed in breast cancer to stratify patients to appropriate therapies and avoid unnecessary toxicity. We used peripheral blood gene expression and cell-type abundance to identify biomarkers of response and recurrence in neoadjuvant chemotherapy–treated patients with breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Axelrod, Margaret L., Wang, Yu, Xu, Yaomin, Sun, Xiaopeng, Bejan, Cosmin A., Gonzalez-Ericsson, Paula I., Nunnery, Sara, Bergman, Riley E., Donaldson, Joshua, Guerrero-Zotano, Angel L., Massa, Chiara, Seliger, Barbara, Sanders, Melinda, Mayer, Ingrid A., Balko, Justin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604512/
https://www.ncbi.nlm.nih.gov/pubmed/36304942
http://dx.doi.org/10.1158/2767-9764.CRC-22-0023
_version_ 1784817832684421120
author Axelrod, Margaret L.
Wang, Yu
Xu, Yaomin
Sun, Xiaopeng
Bejan, Cosmin A.
Gonzalez-Ericsson, Paula I.
Nunnery, Sara
Bergman, Riley E.
Donaldson, Joshua
Guerrero-Zotano, Angel L.
Massa, Chiara
Seliger, Barbara
Sanders, Melinda
Mayer, Ingrid A.
Balko, Justin M.
author_facet Axelrod, Margaret L.
Wang, Yu
Xu, Yaomin
Sun, Xiaopeng
Bejan, Cosmin A.
Gonzalez-Ericsson, Paula I.
Nunnery, Sara
Bergman, Riley E.
Donaldson, Joshua
Guerrero-Zotano, Angel L.
Massa, Chiara
Seliger, Barbara
Sanders, Melinda
Mayer, Ingrid A.
Balko, Justin M.
author_sort Axelrod, Margaret L.
collection PubMed
description Biomarkers of response are needed in breast cancer to stratify patients to appropriate therapies and avoid unnecessary toxicity. We used peripheral blood gene expression and cell-type abundance to identify biomarkers of response and recurrence in neoadjuvant chemotherapy–treated patients with breast cancer. We identified a signature of IFN and complement response that was higher in the blood of patients with pathologic complete response. This signature was preferentially expressed by monocytes in single-cell RNA sequencing. Monocytes are routinely measured clinically, enabling examination of clinically measured monocytes in multiple independent cohorts. We found that peripheral monocytes were higher in patients with good outcomes in four cohorts of patients with breast cancer. Blood gene expression and cell type abundance biomarkers may be useful for prognostication in breast cancer. SIGNIFICANCE: Biomarkers are needed in breast cancer to identify patients at risk for recurrence. Blood is an attractive site for biomarker identification due to the relative ease of longitudinal sampling. Our study suggests that blood-based gene expression and cell-type abundance biomarkers may have clinical utility in breast cancer.
format Online
Article
Text
id pubmed-9604512
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-96045122022-10-26 Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer Axelrod, Margaret L. Wang, Yu Xu, Yaomin Sun, Xiaopeng Bejan, Cosmin A. Gonzalez-Ericsson, Paula I. Nunnery, Sara Bergman, Riley E. Donaldson, Joshua Guerrero-Zotano, Angel L. Massa, Chiara Seliger, Barbara Sanders, Melinda Mayer, Ingrid A. Balko, Justin M. Cancer Res Commun Research Article Biomarkers of response are needed in breast cancer to stratify patients to appropriate therapies and avoid unnecessary toxicity. We used peripheral blood gene expression and cell-type abundance to identify biomarkers of response and recurrence in neoadjuvant chemotherapy–treated patients with breast cancer. We identified a signature of IFN and complement response that was higher in the blood of patients with pathologic complete response. This signature was preferentially expressed by monocytes in single-cell RNA sequencing. Monocytes are routinely measured clinically, enabling examination of clinically measured monocytes in multiple independent cohorts. We found that peripheral monocytes were higher in patients with good outcomes in four cohorts of patients with breast cancer. Blood gene expression and cell type abundance biomarkers may be useful for prognostication in breast cancer. SIGNIFICANCE: Biomarkers are needed in breast cancer to identify patients at risk for recurrence. Blood is an attractive site for biomarker identification due to the relative ease of longitudinal sampling. Our study suggests that blood-based gene expression and cell-type abundance biomarkers may have clinical utility in breast cancer. American Association for Cancer Research 2022-05-04 /pmc/articles/PMC9604512/ /pubmed/36304942 http://dx.doi.org/10.1158/2767-9764.CRC-22-0023 Text en © 2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by/4.0/This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.
spellingShingle Research Article
Axelrod, Margaret L.
Wang, Yu
Xu, Yaomin
Sun, Xiaopeng
Bejan, Cosmin A.
Gonzalez-Ericsson, Paula I.
Nunnery, Sara
Bergman, Riley E.
Donaldson, Joshua
Guerrero-Zotano, Angel L.
Massa, Chiara
Seliger, Barbara
Sanders, Melinda
Mayer, Ingrid A.
Balko, Justin M.
Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer
title Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer
title_full Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer
title_fullStr Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer
title_full_unstemmed Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer
title_short Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer
title_sort peripheral blood monocyte abundance predicts outcomes in patients with breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604512/
https://www.ncbi.nlm.nih.gov/pubmed/36304942
http://dx.doi.org/10.1158/2767-9764.CRC-22-0023
work_keys_str_mv AT axelrodmargaretl peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT wangyu peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT xuyaomin peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT sunxiaopeng peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT bejancosmina peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT gonzalezericssonpaulai peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT nunnerysara peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT bergmanrileye peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT donaldsonjoshua peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT guerrerozotanoangell peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT massachiara peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT seligerbarbara peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT sandersmelinda peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT mayeringrida peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer
AT balkojustinm peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer